Zulassungsantrag für die Behandlung von Anämie bei chronischer Nierenerkrankung basierend auf dem klinischen Phase-III-Studienprogramm ASCEND, bestehend aus fünf Studien, die alle ihre co-primären Wirksamkeits- und Sicherheitsendpunkte erreichten Die Zulassung der EMA-Anträge ist der erste große regulatorische Meilenstein für Daprodustat seit … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged American Society of Nephrology, Anämie, ASCEND-D, ASCEND-ND, Behandlung von Anämie, chronische Nierenerkrankung, CKD, daprodustat, Dialyse, EMA, Europäische Arzneimittel-Agentur, GlaxoSmithKline, Hämoglobin, HIF-PHI, klinisches Studienprogramm ASCEND Phase III, MAA, Prolylhydroxylase-Hemmer, Zulassungsantrag
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?